Physician profile
William A Meeks
NPI 1477993392
$8,248.66
in general payments reported to CMS, 2019-2025
25 companies · $2,109 in 2025
The $2,109 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $12.29 · 2021: $746 · 2022: $892 · 2023: $1,145 · 2024: $3,155 · 2025: $2,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,495 · Travel and Lodging: $793 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,494.77 |
| Travel and Lodging | $793.07 |
| Education | $120.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,539.82 | 2022-2025 | Avvigo Guidance System, Watchman Flx, Opticross |
| Abbott Laboratories | $892.94 | 2019-2025 | Optis, Thoratec Heartmate 3 Lvas Implant Kit, Gallant |
| Medtronic, INC. | $451.87 | 2022-2025 | Corevalve Evolut R, Cobalt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $437.31 | 2022-2025 | Lifevest |
| Edwards Lifesciences Corporation | $435.98 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $372.50 | 2023-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $309.12 | 2021-2023 | Brilinta, Farxiga |
| Shockwave Medical, INC | $308.42 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Teleflex LLC | $293.83 | 2024 | Manta, Trapliner |
| E.R. Squibb & Sons, L.L.C. | $194.12 | 2019-2025 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $169.30 | 2022-2023 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $124.15 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.22 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $121.83 | 2024 | Inpefa |
| Amgen INC. | $114.16 | 2021-2025 | Repatha, Repatha |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $87.56 | 2022-2023 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $67.95 | 2022-2025 | Onpattro, Amvuttra |
| Bridgebio Pharma, INC. | $57.23 | 2025 | Attruby |
| Pfizer INC. | $32.04 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $28.29 | 2019-2021 | |
| Esperion Therapeutics, INC. | $23.33 | 2025 | Nexletol |
| Chiesi USA, INC. | $21.11 | 2025 | Kengreal |
| Merck Sharp & Dohme LLC | $15.99 | 2024 | Verquvo |
| Allergan, INC. | $15.30 | 2019 | |
| La Jolla Pharmaceutical Company | $12.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Meeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.